SCHEMBL829346

SCHEMBL829346

O=C(Oc1cc(Cl)c(Cl)cc1Cl)N1CCc2ccccc2C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.57
ALDH1A1 P00352 3/20 0.57
HTT P42858 3/20 0.57
LMNA P02545 1/20 0.57
RAB9A P51151 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HSP90AA1 P07900 1/20 0.51
NOTUM Q6P988 1/20 0.50
ABHD6 Q9BV23 1/20 0.50
SPR P35270 1/20 0.50
TAS1R3 Q7RTX0 2/20 0.49
TAS1R1 Q7RTX1 2/20 0.49
TAS1R2 Q8TE23 2/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPT P10636 1/20 0.49
TAAR1 Q96RJ0 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
NPC1 O15118 1/20 0.47
CASP3 P42574 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28052473 0.83 HTT (0.52) HPGDALDH1A1HTTLMNARAB9A
SCHEMBL29591380 0.83 HTT (0.52) HPGDALDH1A1HTTLMNARAB9A
SCHEMBL830651 0.81 SPR (0.60) HPGDALDH1A1HTTLMNARAB9A
SCHEMBL829878 0.78 NPC1 (0.53) HPGDALDH1A1LMNARAB9ASMN1; SMN2
SCHEMBL28826015 0.78 LIPE (0.62) HPGDALDH1A1HTTLMNASMN1; SMN2
SCHEMBL15355311 0.77 SMN1; SMN2 (0.59) HPGDALDH1A1HTTLMNARAB9A
SCHEMBL29589853 0.77 SMN1; SMN2 (0.59) HPGDALDH1A1HTTLMNARAB9A
SCHEMBL28208068 0.76 NOTUM (0.62) HPGDALDH1A1HTTLMNARAB9A
SCHEMBL28052485 0.75 POLB (0.50) HPGDALDH1A1RAB9ASMN1; SMN2NOTUM
SCHEMBL828934 0.75 MAPT (0.55) HPGDALDH1A1HTTLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 HPGD 461/4885ALDH1A1 936/4885HTT 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.